Bayer Aktiengesellschaft

Troponwerke Gmbh & Co Kg

Troponwerke Dinklage & Company

Troponwerke Gmbh & Co.

Peter-Rudolf Seidel

Thomas Glaser

Jorg Traber

Rudolf Schohe-Loop

Joachim Schuhmacher

Teunis Schuurman

Rudolf Schohe

Achim Feurer

Bernard Schmidt

Wolfgang Dompert

Franz-Josef Van Der Staay

William Bullock

Jane C Chisholm

Georg Terstappen

Richard J Fanelli

Richard T McCarthy

Bodo Junge

Harald Horstmann

Karl-Heinz Boltze

Ulrich Benz

Haireddin Jacobi

Hans-Georg Lerchen

Hans-Georg Heine

Jean-Marie Viktor De Vry

Helmut Schwarz

Gunter Schollnhammer

Jean-Marie V De Vry

Walter Hubsch

Siegfried Raddatz

Henning Sommermeyer

Reinhard Jork

Arno Friedl

Hans-Dieter Dell

Jean M De Vry

Wolfgang Roben

Gabriele Handke

Wolfgang Kanhai

Ervin Horvath

Otfried Brendler

J Org Traber

Helmut H Schwarz

Teunis Schuurmann

Teunis Thurman

The present invention relates to bis-(quinolyl)-diamines of the general formula (I):

Bis-(quinolyl)-diamines

The benzisothiazolyl-substituted aminomethylchromans are prepared either by substituting the corresponding unsubstituted aminomethylchromans on the amine nitrogen or reacting the corresponding benzisothiazolylalkylamines with appropriate activated methylchromans or reacting the amine nitrogen of aminomethylchroman first with an appropriately substituted alkine and then hydrogenating. The benzisothiazolyl-substituted aminomethylchromans can be used as active compounds in medicaments, in particular in medicaments for the treatment of disorders of the central nervous system.

Benzisothiazolyl-substituted aminomethylchromans

The present invention relates to 2,2'-bridged bis-2,4-diaminoquinazolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides processes for the preparation of the compounds of the formula (I), their use for the preparation of drugs, and drugs containing said compounds.

2,2'-bridged bis-2,4-diaminoquinazolines

The present invention relates to ring-bridged bis-quinolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides a process for the preparation of compounds of the formula (I), their use for the preparation of drugs, and drugs containing said compounds.

Ring-bridged bis-quinolines

4,4'-Bridged bis-2,4-diaminoquinazolines of the general formula (I) ##STR1## processes for their preparation and use as agents acting on the potassium channels of the brain.

4, 4'-bridged bis-2, 4-diaminoquinazolines

The present invention relates to the use of bisquinolines of the general formula ##STR1## in which the substituents mentioned have the meanings given in the description. The invention furthermore relates to new bisquinolines of the general formula (I), to a process for the preparation of the known and the new bisquinolines, to the use of the new bisquinolines as medicaments, to their use for the preparation of medicaments, and to medicaments comprising them.

Use of bisquinoline compounds in the treatment of cerebral disorders

The present invention provides 2,4'-bridged bis-2,4-diaminoquinazolines of the general formula (I): ##STR1## in which the indicated substituents are as defined in the description. The invention also provides a process for the preparation of the compounds of the formula (I), drugs containing said compounds and processes for the preparation of drugs containing said compounds.

2,4'-bridged bis-2,4-diaminoquinazolines

The method of treating stroke in a patient suffering therefrom by administering a substituted aminomethylchroman of the formula ##STR1## in which Z--denotes a group of the formula ##STR2## R.sup.1, E and F can be hydrogen or other radicals, or salts thereof.

Substituted aminomethyltetralins and their heterocyclic analogues

A method of treating depression or stroke in a patient suffering therefrom by administering a substituted aminomethylchroman of the formula ##STR1## in which Z--denotes a group of the formula ##STR2## and R.sup.1, E and F can be hydrogen or other radicals, or salts thereof.

Method for treating depression using substituted aminomethyltetralins

Novel 1,3-disubstituted pyrrolidines active on the central nervous system of the formula ##STR1## wherein A--denotes phenyl or hetaryl, which is optionally fused with aromatic, saturated or unsaturated cyclic or heterocyclic hydrocarbons, where this radical can optionally be substituted,

1,3-disubstituted pyrrolidines

Piperidylmethyl-substituted chroman derivatives can be prepared by first reducing corresponding chromancarboxylic acid derivatives, if appropriate with prior activation, with the cyclic amines and then reducing the carbonyl group, or by reacting chromanmethyl compounds directly with the cyclic amines. The substituted piperidylmethyl-substituted chroman derivatives can be employed as active compounds in medicaments, in particular for the treatment of diseases of the central-nervous system.

Piperidylmethyl-substituted chroman derivatives

The invention relates to substituted 2-pyrimidinyl-1-piperazine derivatives defined herein by formula (I), processes for their manufacture, compositions containing said substituted 2-pyrimidinyl-1-piperazine derivatives as active materials and the use of said compounds and compositions as agents effecting the central nervous system. Also included in the invention are intermediates of formula (VIII) for making the active formula (I) compounds.

2-pyrimidinyl-1-piperazine derivatives processes for their preparation

For binding 5-HT.sub.1 receptors and thereby treating central nervous system disorders, novel substituted aminomethyltetralins and their heterocyclic analogues of the formula ##STR1##

2-pyrimidinyl-1-piperazine derivatives

Growing community of inventors

Cologne, Germany

Peter-Rudolf Seidel